Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Kristijan Ramadan and his group published a new article in The EMBO Journal today. The article adds new detail to the story of how our cells repair damage to our DNA.

All day every day cells must detect and repair DNA damage. DNA damage comes in several forms, but the most dangerous and the most relevant for radiotherapy is DNA double strand breaks.

Repairing DNA damage is a team game, with a number of proteins coming together to regulate and carry out the repair. These proteins are vital for the repair, but accumulation of too much of these proteins will cause issues such as genome instability, which can promote both tumour genesis and tumour progression.

RING finger protein 8 (RNF8) is an integral part of the DNA repair process, but it must not be allowed to accumulate in a cell.

Kristijan and his group have uncovered how the cell maintains just the right amount of RNF8. A combination of two proteins, p97 and ATX3 work together to adjust levels of RNF8. Inactivation of the p97-ATX3 combination prevents the cells from regulating the amount of RNF8 and makes the cells very sensitive to radiation.

Since many cancers have evolved to rely heavily on the DNA repair that RNF8 facilitates, this suggests an interesting target for cancer therapy. A target that should hurt cancer cells very much more than healthy ones.

 

 

Abhay Narayan Singh, Judith Oehler, Ignacio Torrecilla, Susan Kilgas, Shudong Li, Bruno Vaz, Claire Guérillon, John Fielden, Esperanza HernandezCarralero, Elisa Cabrera, Iain DC Tullis, Mayura Meerang, Paul R Barber, Raimundo Freire, Jason Parsons, Borivoj Vojnovic, Anne E Kiltie, Niels Mailand, Kristijan Ramadan. (2019) The p97–Ataxin 3 complex regulates homeostasis of the DNA damage response E3 ubiquitin ligase RNF8. EMBO J (2019): e102361

https://www.embopress.org/doi/10.15252/embj.2019102361

Similar stories

Machine Learning Enhances Detection of Multiple Cancer Types from Blood

Researchers from the University of Oxford have developed TriOx, a highly sensitive blood test that detects six cancers at their earliest stages. Published today in Nature Communications, the findings highlight the test’s potential to transform early cancer detection and improve patient outcomes.

Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer

The Oncology Department at the University of Oxford is excited to announce the forthcoming publication in the Proceedings of the National Academy of Sciences (PNAS) of the research paper “Goblet Cell Differentiation Subgroups in Colorectal Cancer.” This groundbreaking study sheds light on the role of goblet cell differentiation in colorectal cancer (CRC) and its impact on cancer progression and prognosis.

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).

Subashan Vadibeler wins 2024 Lasker Essay Contest

Subashan Vadibeler, a recent Oxford Rhodes scholar and Department of Oncology student, is one of five co-winners of the international 2024 Lasker Essay Contest, sponsored by the Lasker Foundation.

Glowing dye helps surgeons eradicate prostate cancer

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.

New funding for development of world's first lung cancer vaccine

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.